GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (NAS:ABUS) » Definitions » Cyclically Adjusted PB Ratio

Arbutus Biopharma (Arbutus Biopharma) Cyclically Adjusted PB Ratio : 0.83 (As of May. 16, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Arbutus Biopharma Cyclically Adjusted PB Ratio?

As of today (2024-05-16), Arbutus Biopharma's current share price is $2.81. Arbutus Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $3.38. Arbutus Biopharma's Cyclically Adjusted PB Ratio for today is 0.83.

The historical rank and industry rank for Arbutus Biopharma's Cyclically Adjusted PB Ratio or its related term are showing as below:

ABUS' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.24   Med: 0.91   Max: 8.34
Current: 0.84

During the past years, Arbutus Biopharma's highest Cyclically Adjusted PB Ratio was 8.34. The lowest was 0.24. And the median was 0.91.

ABUS's Cyclically Adjusted PB Ratio is ranked better than
66.87% of 646 companies
in the Biotechnology industry
Industry Median: 1.76 vs ABUS: 0.84

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Arbutus Biopharma's adjusted book value per share data for the three months ended in Mar. 2024 was $0.636. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.38 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Arbutus Biopharma Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Arbutus Biopharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arbutus Biopharma Cyclically Adjusted PB Ratio Chart

Arbutus Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.77 1.08 1.13 0.64 0.71

Arbutus Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.83 0.63 0.56 0.71 0.76

Competitive Comparison of Arbutus Biopharma's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Arbutus Biopharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arbutus Biopharma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Arbutus Biopharma's Cyclically Adjusted PB Ratio falls into.



Arbutus Biopharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Arbutus Biopharma's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.81/3.38
=0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arbutus Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Arbutus Biopharma's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.636/129.4194*129.4194
=0.636

Current CPI (Mar. 2024) = 129.4194.

Arbutus Biopharma Quarterly Data

Book Value per Share CPI Adj_Book
201406 4.762 100.560 6.129
201409 4.286 100.428 5.523
201412 3.923 99.070 5.125
201503 10.975 99.621 14.258
201506 10.837 100.684 13.930
201509 10.149 100.392 13.084
201512 10.036 99.792 13.016
201603 9.850 100.470 12.688
201606 7.871 101.688 10.017
201609 7.597 101.861 9.652
201612 3.702 101.863 4.703
201703 3.437 102.862 4.324
201706 3.195 103.349 4.001
201709 3.041 104.136 3.779
201712 2.410 104.011 2.999
201803 2.070 105.290 2.544
201806 2.056 106.317 2.503
201809 1.655 106.507 2.011
201812 1.307 105.998 1.596
201903 0.912 107.251 1.101
201906 0.566 108.070 0.678
201909 -0.893 108.329 -1.067
201912 -0.996 108.420 -1.189
202003 -0.956 108.902 -1.136
202006 -1.074 108.767 -1.278
202009 -0.571 109.815 -0.673
202012 -0.522 109.897 -0.615
202103 -0.395 111.754 -0.457
202106 -0.557 114.631 -0.629
202109 -0.277 115.734 -0.310
202112 1.169 117.630 1.286
202203 1.115 121.301 1.190
202206 1.029 125.017 1.065
202209 0.953 125.227 0.985
202212 0.869 125.222 0.898
202303 0.872 127.348 0.886
202306 0.807 128.729 0.811
202309 0.712 129.860 0.710
202312 0.624 129.419 0.624
202403 0.636 129.419 0.636

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Arbutus Biopharma  (NAS:ABUS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Arbutus Biopharma Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Arbutus Biopharma's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arbutus Biopharma (Arbutus Biopharma) Business Description

Traded in Other Exchanges
Address
701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
Executives
Melissa Rewolinski director 9000 STATE ROAD, PHILADELPHIA PA 19136
Karen Sims officer: Chief Medical Officer 701 VETERANS CIRCLE, WARMINSTER PA 18974
J. Christopher Naftzger officer: General Counsel and CCO 633 LOWTHER ROAD, LEWISBERRY PA 17339
Michael J. Sofia officer: Chief Scientific Officer C/O ARBUTUS BIOPHARMA CORP., SUITE 100, 8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Tram Tran director C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974
Roivant Sciences Ltd. 10 percent owner CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Michael J. Mcelhaugh officer: Chief Business Officer C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902
Eric Venker director C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
James R Meyers director GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Andrew Cheng director 170 HARBOR WAY, 3RD FLOOR, C/O AKERO THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080
Myrtle S Potter director 10 FINDERNE AVE, BRIDGEWATER NJ 08807
William H. Collier director, officer: President and CEO C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974
Elizabeth Howard officer: Executive VP & General Counsel 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
David C Hastings officer: Chief Financial Officer C/O ARBUTUS BIOPHARMA, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Gaston Picchio officer: Chief Development Officer C/O ARBUTUS BIOPHARMA CORP, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8